BioVie Reports Data From Phase 2 ADDRESS-LC Trial Of Bezisterim At 151st Annual Meeting Of American Neurological Association

BioVie Inc. (NASDAQ: BIVI) presented results from its Phase 2 ADDRESS-LC study evaluating bezisterim (NE3107) for Long COVID at the 151st Annual Meeting of the American Neurological Association held from October 17–20, 2026, in San Diego, California. The study's abstract was published in the Annals of Neurology, highlighting the company's ongoing efforts in developing innovative therapies for neurological diseases.